CARMAT news, videos and press releases
For more news please use our advanced search feature.
CARMAT - More news...
CARMAT - More news...
- CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson® Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support
- CARMAT to Provide a Business Update and Host a Videoconference on April 9, 2025
- CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment
- CARMAT: Aeson® total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation
- CARMAT Achieves the Milestone of 100 Implants of Its Aeson® Total Artificial Heart
- CARMAT Raises a Total of €9.7 Million
- CARMAT Launches a €10 Million Global Offering With €7 Million in Subscription Commitments
- CARMAT: 2025 Financial Calendar
- CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025
- CARMAT Delivers a Solid FY 2024 with 42 Implants of Its Aeson® Artificial Heart and Anticipates Continued Strong Momentum in 2025
- CARMAT optimizes its financial structure by buying-back, for a symbolic sum of one euro, 2 million shares from Matra-Défense (Airbus group) which will be allocated to the repayment of its financial debt
- Successful first “Aeson® European User Meeting”, marking an important step in the deployment of CARMAT's artificial heart
- CARMAT's Aeson® Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe
- CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at Its Annual General Meeting
- CARMAT Obtains Non-dilutive Financing of €13.2 Million Within the Framework of the “France 2030” Plan
- CARMAT: Availability of the 2022 Universal Registration Document
- CARMAT: The First U.S. Clinical Experience with Aeson® TAH Published in the Annals of Thoracic Surgery Short Reports
- CARMAT Announces Its 2022 Annual Results and Confirms Its 2023 Objectives
- CARMAT Provides a Business Update and Communicates Its Financial Targets for the First Time
- CARMAT will hold a video conference on January 23 at 8 pm CET to provide a business update
- CARMAT: 2023 Financial Calendar
- CARMAT Announces the First Implantation of Aeson® Within the Framework of The EFICAS Clinical Study in France
- CARMAT Announces the Appointment of Alexandre Conroy as Chairman of the Board of Directors
- CARMAT Gets Blended Funding of up to €17.5m as a Winner of the European Innovation Council (EIC) Accelerator
- CARMAT Successfully Raises a Total of €31.1 Million via the Issuance of 2,960,710 Shares
- CARMAT Launches a Global Offering for an Amount of c. €30 Million That Has Received Subscription Commitments Totaling €5.5 Million
- CARMAT Announces the Resumption of Commercial Implants of its Aeson® Artificial Heart Is Now Effective
- CARMAT Announces That It Has Received Regulatory Approvals to Resume Its Clinical Study in France
- CARMAT Announces That It Has Received the Necessary Regulatory Approvals to Resume Aeson® Commercial Implants
- CARMAT Announces Three Publications About Aeson® in Peer-Reviewed Scientific Journals
